Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Xiao, Mang ^a   Zhang, Lei ^a   Zhu, Xinhua ^b   Huang, Jun ^a   Jiang, Huifen ^c   Hu, Sunhong ^a   Liu, Yuehui ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN; MESSENGER RNA; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; POPULATION RESEARCH; AGED; BIOSYNTHESIS; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NASOPHARYNX TUMOR; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77950898801     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-147     Document Type: Article

References (33)

1. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009, 137:609-622. 10.1016/j.cell.2009.04.050, 19450511.
2. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-604. 10.1038/nrc864, 12154352.
3. Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, Moore D, Millikan RC, Cance WG. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer 2009, 125:1735-1738. 10.1002/ijc.24486, 2773794, 19521985.
4. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19:607-614. 10.1002/humu.10081, 12007217.
5. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood 1991, 77:1153-1156.
6. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602. 10.1016/j.cell.2004.11.022, 15550242.
7. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365. 10.1038/ng1093, 12567188.
8. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005, 65:9582-9587. 10.1158/0008-5472.CAN-05-1460, 16230424.
9. Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, Wang J. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 2009, 33:1454-1458. 10.1016/j.leukres.2009.04.007, 19423162.
10. Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis 2008, 29:2120-2125. 10.1093/carcin/bgn191, 2577141, 18701437.
11. Greene FL, Page DL, Fleming ID, Haller DG, Morrow M. AJCC Cancer Staging Manual. 2002, 6. New York: Springer - Verlag.
12. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990, 18:4961. 10.1093/nar/18.16.4961, 332028, 1975675.
13. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001, 29:E88-8. 10.1093/nar/29.17.e88, 55900, 11522844.
14. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001, 25:409-418. 10.1006/meth.2001.1263, 11846610.
15. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?. Carcinogenesis 2002, 23:381-387. 10.1093/carcin/23.3.381, 11895852.
16. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238. 10.1126/science.1978757, 1978757.
17. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 1993, 66:83-92. 10.1016/0165-4608(93)90233-C, 8500106.
18. Runnebaum IB, Tong XW, Moebus V, Heilmann V, Kieback DG, Kreienberg R. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum Genet 1994, 93:620-624. 10.1007/BF00201559, 8005584.
19. Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008, 261:21-25. 10.1016/j.canlet.2007.10.044, 18248785.
20. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221. 10.1038/356215a0, 1552940.
21. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999, 59:1-7.
22. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998, 26:3453-3459. 10.1093/nar/26.15.3453, 147746, 9671804.
23. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999, 19:1092-1100. 116039, 9891044.
24. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006, 27:110-117. 10.1002/humu.20277, 16287156.
25. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007, 28:1996-2001. 10.1093/carcin/bgm168, 17638920.
26. Bittenbring J, Parisot F, Wabo A, Mueller M, Kerschenmeyer L, Kreuz M, Truemper L, Landt O, Menzel A, Pfreundschuh M, Roemer K. MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer 2008, 8:116. 10.1186/1471-2407-8-116, 2375899, 18433491.
27. Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008, 26:2252-2257. 10.1200/JCO.2007.11.5212, 18467716.
28. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 2007, 16:2717-2723. 10.1158/1055-9965.EPI-07-0634, 18086778.
29. Zhuo XL, Cai L, Xiang ZL, Zhuo WL, Wang Y, Zhang XY. TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch Med Res 2009, 40:299-305. 10.1016/j.arcmed.2009.03.006, 19608020.
30. Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer 2008, 44:760-766. 10.1016/j.ejca.2008.02.007, 18313915.
31. Zhou G, Zhai Y, Cui Y, Zhang X, Dong X, Yang H, He Y, Yao K, Zhang H, Zhi L, Yuan X, Qiu W, Zhang X, Shen Y, Qiang B, He F. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 2007, 13:2627-2633. 10.1158/1078-0432.CCR-06-2281, 17473193.
32. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995, 85:1580-1589.
33. Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 2007, 67:5831-5839. 10.1158/0008-5472.CAN-06-4533, 17575151.